Recap: Heart Test Laboratories Q3 Earnings
Portfolio Pulse from Benzinga Insights
Heart Test Laboratories (NASDAQ:HSCS) reported Q3 earnings, beating estimates with an EPS of $-0.03 versus the expected $-0.06, and revenue increased by $12 thousand year-over-year. Despite missing EPS estimates last quarter, the share price increased by 12.0% the following day.
March 14, 2024 | 9:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Heart Test Laboratories reported better than expected Q3 earnings with an EPS of $-0.03, surpassing estimates by 50%, and a year-over-year revenue increase of $12 thousand.
The positive earnings report, beating estimates by a significant margin and showing revenue growth, is likely to instill investor confidence and could lead to a short-term increase in stock price, similar to the 12% rise observed after the last quarter's earnings announcement despite missing EPS estimates.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100